Tilray, Inc. - Class 2 (TLRY): Price and Financial Metrics

Tilray, Inc. - Class 2 (TLRY): $11.68

0.46 (+4.10%)

POWR Rating

Component Grades














  • Growth is the dimension where TLRY ranks best; there it ranks ahead of 61.56% of US stocks.
  • The strongest trend for TLRY is in Momentum, which has been heading up over the past 31 weeks.
  • TLRY ranks lowest in Sentiment; there it ranks in the 4th percentile.

TLRY Stock Summary

  • Tilray Inc's stock had its IPO on July 19, 2018, making it an older stock than merely 7.98% of US equities in our set.
  • TLRY's price/sales ratio is 34.7; that's higher than the P/S ratio of 93.12% of US stocks.
  • The volatility of Tilray Inc's share price is greater than that of 95.73% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to TLRY, based on their financial statements, market capitalization, and price volatility, are BIOL, NOV, FOLD, OTRK, and PGEN.
  • TLRY's SEC filings can be seen here. And to visit Tilray Inc's official web site, go to www.tilray.com.

TLRY Valuation Summary

  • TLRY's price/sales ratio is 29.5; this is 719.44% higher than that of the median Healthcare stock.
  • TLRY's price/earnings ratio has moved up 76.4 over the prior 37 months.
  • Over the past 37 months, TLRY's EV/EBIT ratio has gone up 84.7.

Below are key valuation metrics over time for TLRY.

Stock Date P/S P/B P/E EV/EBIT
TLRY 2021-06-09 46.4 17.7 -22.4 -23.8
TLRY 2020-08-05 5.2 5.3 -2.1 -3.0
TLRY 2019-11-21 16.6 5.4 -17.1 -24.3
TLRY 2019-03-21 233.2 34.8 -288.4 -307.2
TLRY 2019-03-01 263.9 39.4 -326.5 -348.2
TLRY 2018-09-28 476.6 379.7 -589.6 -637.7

TLRY Price Target

For more insight on analysts targets of TLRY, see our TLRY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.38 Average Broker Recommendation 1.86 (Hold)

TLRY Stock Price Chart Interactive Chart >

Price chart for TLRY

TLRY Price/Volume Stats

Current price $11.68 52-week high $67.00
Prev. close $11.22 52-week low $4.41
Day low $11.25 Volume 7,023,490
Day high $11.69 Avg. volume 28,499,473
50-day MA $13.49 Dividend yield N/A
200-day MA $17.47 Market Cap 5.23B

Tilray, Inc. - Class 2 (TLRY) Company Bio

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was founded in 2018 and is based in Nanaimo, Canada.

TLRY Latest News Stream

Event/Time News Detail
Loading, please wait...

TLRY Latest Social Stream

Loading social stream, please wait...

View Full TLRY Social Stream

Latest TLRY News From Around the Web

Below are the latest news stories about Tilray Inc that investors may wish to consider to help them evaluate TLRY as an investment opportunity.

Tilray’s $4B Revenue Target Needs More Than Organic Growth

Tilray stock investors should prepare for dilution or disappointment as the company targets generating $4 billion in revenue for Fiscal Year 2024.

Brian Paradza, CFA on InvestorPlace | September 21, 2021

Tilray Anywhere Near $12 Is an Absolute Steal

The skeptics will fret over a vote allowing more TLRY stock shares to be issued.

David Moadel on InvestorPlace | September 20, 2021

Why Aurora Cannabis, Canopy Growth, and Tilray Stock Tumbled Today

As of 11:05 a.m. EDT, shares of Canopy Growth (NASDAQ: CGC) have fallen 5.8%, Tilray (NASDAQ: TLRY) is down 6%, and Aurora Cannabis (NASDAQ: ACB) is bringing up the rear with a 6.3% decline. The past several days have seen a series of cuts to marijuana stock price targets among Wall Street analysts, you see, in advance of Aurora Cannabis' upcoming fiscal fourth-quarter 2021 earnings report (due out tomorrow). The bad news began back on Thursday, when Roth Capital cut its price target on Tilray in half, to $12 a share, commenting that management's sales projections for fiscal 2024 were too "hopeful" to be true.

Yahoo | September 20, 2021

Tilray Gains on Aphria Merger, Global Cannabis Operations

Tilray (TLRY) is a large-scale Canadian cannabis LP with global operations. It holds first place among other cannabis producers in geographic footprint, and Canadian cannabis market share. The company significantly increased its size and revenue through a recent merger with Aphria, another large Canadian LP. Tilray made news when its stock rose from $7 per share to $67 per share between January and February of this year. The stock price currently sits around $12 per share, as investors digest its new valuation and long-term potential. (See TLRY stock charts on TipRanks) Although its stock has been down over the summer, I maintain a bullish rating.

Alan Sumler on TipRanks | September 17, 2021

Tilray Bolsters Distribution Partnership With ROSE LifeScience In Quebec

Tilray Inc.''s (NASDAQ: TLRY ) (TSX: TLRY) is expanding its distribution partnership with Quebec-based ROSE LifeScience Inc through its subsidiary Tilray Canada Ltd. Under the deal, ROSE became an official partner to the recently created new entity. ROSE agreed to represent the entire Tilray product portfolio in Quebec, including Grail, Marley Natural, Dubon, La Batch, Broken Coast, Riff, Solei, Good Supply, B!NGO and P''tite Pof. "Expanding new business in Québec is always exciting," said ROSE LifeScience president and CEO Davide Zaffino of the partnership, which includes the sale, supply, Full story available on Benzinga.com

Benzinga | September 17, 2021

Read More 'TLRY' Stories Here

TLRY Price Returns

1-mo -12.64%
3-mo -36.04%
6-mo -47.10%
1-year 117.71%
3-year -90.50%
5-year N/A
YTD 41.40%
2020 -51.78%
2019 -75.72%
2018 N/A
2017 N/A
2016 N/A

Continue Researching TLRY

Want to see what other sources are saying about Tilray Inc's financials and stock price? Try the links below:

Tilray Inc (TLRY) Stock Price | Nasdaq
Tilray Inc (TLRY) Stock Quote, History and News - Yahoo Finance
Tilray Inc (TLRY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8366 seconds.